Innovative regenerative medicines in the EU: a better future in evidence? - Test2 - elhamkhani - TriplyDB

Innovative regenerative medicines in the EU: a better future in evidence?

Innovative regenerative medicines in the EU: a better future in evidence?

http://www.wikidata.org/entity/Q36300179

about

Distributive justice and regenerative medicine.Global Regulatory Differences for Gene- and Cell-Based Therapies: Consequences and Implications for Patient Access and Therapeutic Innovation.Registry Contributions to Strengthen Cell and Gene Therapeutic Evidence.Advantages of Graphene Biosensors for Human Stem Cell Therapy Potency Assays.

P2860

Q47630230-B78AB144-5EED-41BF-937D-A0AB54B25DBC Q49566187-C918DEB1-553D-44EF-8F7F-6DF8A84B67AC Q52804455-36F7FA04-ABEA-439B-8077-30486344A314 Q55554954-6B477C5A-8FCE-4A85-93F4-E4C666DAC3FE

P2860

Innovative regenerative medicines in the EU: a better future in evidence?

http://www.wikidata.org/entity/Q36300179

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Innovative regenerative medicines in the EU: a better future in evidence?

@ast

Innovative regenerative medicines in the EU: a better future in evidence?

@en

type

label

Innovative regenerative medicines in the EU: a better future in evidence?

@ast

Innovative regenerative medicines in the EU: a better future in evidence?

@en

prefLabel

Innovative regenerative medicines in the EU: a better future in evidence?

@ast

Innovative regenerative medicines in the EU: a better future in evidence?

@en

P1433

Q36300179-2E6807D0-0A47-4C3E-AC73-188490E1EBE5

P1476

Q36300179-E104213F-1BA6-4A1A-B9D3-19CB5AE8E37D

P2093

Q36300179-16154E95-78EF-41C6-9B62-DEF733F337C2

Q36300179-A46C5193-4766-4070-999B-51EE676D1BB8

Q36300179-DE2406E1-764C-4F4D-A7E5-6F7A6B86B22B

Q36300179-F042F818-60CA-4C59-9754-734ADC101F8E

P2860

Q36300179-0A1449D1-F4B8-458D-90CA-CA065842DA98

Q36300179-0ABDC94D-1ACE-4E12-9C01-669C9A4BB392

Q36300179-0ECD7095-AD99-42EC-812C-8B96582104D6

Q36300179-0F9380FE-DCF6-4D3C-9056-B3A9DEE28980

Q36300179-3D4A365A-B408-407A-B5B0-45B0E4812B6E

Q36300179-4545659A-ACF5-4061-9E03-7A3727F71290

Q36300179-4583EAAC-FA46-432E-9ACF-72AB0946C94F

Q36300179-4DDCCFDA-B5D4-4B54-BCD8-6FAD0D9E85D8

Q36300179-52F6606A-9BD6-4914-9D14-7ADC964D3D23

Q36300179-5586B8AF-2202-4FFF-922F-E58742FB6144

P2888

Q36300179-B54C4D64-9C74-41F0-90D4-3E1FDB43C0DF

P304

Q36300179-9DE376C0-62B2-4D1B-BD94-8B32A9D0841A

P31

Q36300179-41AF15BD-694D-43ED-BAAB-8491211FC807

Q36300179-da64de1c-aa37-43f8-a5c2-518d6f36d2c8

P356

Q36300179-6A9ADDA8-72A0-48D5-9268-04C95434405B

P407

Q36300179-0D2986D3-0DAB-4051-99D4-BC9A9DC4FD89

P433

Q36300179-8944A565-EF40-45E3-A640-7EC20F6DC9F3

P478

Q36300179-6A296393-8F49-4661-964E-73ABFC95719D

P577

Q36300179-3A57F257-8411-480F-8774-6C0ABE60AF51

P6179

Q36300179-CE309FBC-2773-4244-BA19-A09EF54F0B3A

P698

Q36300179-E712E058-29B3-4890-92F9-152F675A5AAB

P932

Q36300179-039B9FA9-9263-41A9-8F1C-AF2AD1C013E8

P356

S12916-017-0818-4

P1433

P1476

Innovative regenerative medicines in the EU: a better future in evidence?

@en

P2093

Andrew Webster

http://www.w3.org/2001/XMLSchema#string

Mark S Corbett

http://www.w3.org/2001/XMLSchema#string

Nerys Woolacott

http://www.w3.org/2001/XMLSchema#string

Robert Hawkins

http://www.w3.org/2001/XMLSchema#string

P2860

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

Single-center trials tend to provide larger treatment effects than multicenter trials: a systematic review.

Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force.

The survey on cellular and engineered tissue therapies in Europe in 2012.

Clinical development of advanced therapy medicinal products in Europe: evidence that regulators must be proactive

Concise review: cell therapies: the route to widespread adoption.

Use of surrogate outcomes in cost-effectiveness models: a review of United Kingdom health technology assessment reports.

Assessing the value of autologous and allogeneic cells for regenerative medicine.

A framework for applying unfamiliar trial designs in studies of rare diseases.

Regulation of advanced therapy medicinal products in Europe and the role of academia.

P2888

s12916-017-0818-4

P304

49

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12916-017-0818-4

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P577

2017-03-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1083941587

http://www.w3.org/2001/XMLSchema#string

P698

28270209

http://www.w3.org/2001/XMLSchema#string

P932

5341436

http://www.w3.org/2001/XMLSchema#string